Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Journey Medical Corporation (DERM : NSDQ)
 
 • Company Description   
Journey Medical Corporation is a commercial-stage pharmaceutical company. It focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Journey Medical Corporation is based in Scottsdale, Arizona.

Number of Employees: 41

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.11 Daily Weekly Monthly
20 Day Moving Average: 196,100 shares
Shares Outstanding: 26.31 (millions)
Market Capitalization: $239.68 (millions)
Beta: 0.80
52 Week High: $9.30
52 Week Low: $3.54
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 26.35% 23.04%
12 Week 31.08% 25.64%
Year To Date 132.99% 103.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9237 E VIA DE VENTURA BLVD. SUITE 105
-
SCOTTSDALE,AZ 85258
USA
ph: 480-434-6670
fax: -
ir@jmcderm.com http://www.jmcderm.com
 
 • General Corporate Information   
Officers
Claude Maraoui - Chief Executive Officer; President and Director
Lindsay A. Rosenwald - Executive Chairman
Joseph Benesch - Chief Financial Officer
Neil Herskowitz - Director
Justin Smith - Director

Peer Information
Journey Medical Corporation (GSAC)
Journey Medical Corporation (CASI)
Journey Medical Corporation (ALCD.)
Journey Medical Corporation (OMNN)
Journey Medical Corporation (CGPI.)
Journey Medical Corporation (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 48115J109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/12/25
Share - Related Items
Shares Outstanding: 26.31
Most Recent Split Date: (:1)
Beta: 0.80
Market Capitalization: $239.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.41 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 11.11
Price/Cash Flow: -
Price / Sales: 4.25
EPS Growth
vs. Year Ago Period: 5.88%
vs. Previous Quarter: 11.11%
Sales Growth
vs. Year Ago Period: 1.04%
vs. Previous Quarter: 14.23%
ROE
09/30/25 - -
06/30/25 - -48.69
03/31/25 - -52.03
ROA
09/30/25 - -
06/30/25 - -11.26
03/31/25 - -11.28
Current Ratio
09/30/25 - -
06/30/25 - 1.27
03/31/25 - 1.34
Quick Ratio
09/30/25 - -
06/30/25 - 0.95
03/31/25 - 1.03
Operating Margin
09/30/25 - -
06/30/25 - -15.49
03/31/25 - -14.76
Net Margin
09/30/25 - -
06/30/25 - -15.49
03/31/25 - -14.76
Pre-Tax Margin
09/30/25 - -
06/30/25 - -15.28
03/31/25 - -14.65
Book Value
09/30/25 - -
06/30/25 - 0.82
03/31/25 - 0.93
Inventory Turnover
09/30/25 - -
06/30/25 - 1.46
03/31/25 - 1.63
Debt-to-Equity
09/30/25 - -
06/30/25 - 1.11
03/31/25 - 1.07
Debt-to-Capital
09/30/25 - -
06/30/25 - 52.60
03/31/25 - 51.75
 

Powered by Zacks Investment Research ©